Skip to main content

Aetna to Cover Veracyte Thyroid Cancer Test

NEW YORK (GenomeWeb News) – Veracyte announced today that Aetna will provide its members with coverage for the firm's Afirma Gene Expression Classifier, a genomic test used to clarify results as benign or suspicious for cancer.

The Afirma Gene Expression Classifier is part of Veracyte's Afirma Thyroid FNA Analysis, which combines specialist cytopathology assessment of thyroid nodule FNA samples with the Afirma test. According to the South San Francisco, Calif.-based firm, Aetna issued a positive coverage policy for the test, making it available to the insurer's estimated 22 million medical members for use in assessing thyroid nodule fine needle aspiration biopsies that are indeterminate following traditional cytopathology review.

The coverage policy became effective last month.

Veracyte said that including the coverage decision by Aetna the Afirma Gene Expression Classifier is now covered for approximately 110 million patients nationwide, including through Medicare, UnitedHealthcare and other, smaller private plans.

Veracyte recently completed the final tranche of its Series C financing round raising $28 million.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.